- KRN 633
-
-
2026-06-30
- CAS:286370-15-8
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1000kg
- KRN-633
-
- $41.00
-
2026-05-11
- CAS:286370-15-8
- Purity: 99.53%
- Supply Ability: 10g
- KRN 633
-
- $1000.00
-
2019-07-06
- CAS:286370-15-8
- Min. Order: 1G
- Purity: 98%
- Supply Ability: 100kg
|
| | KRN 633 Basic information |
| Product Name: | KRN 633 | | Synonyms: | KRN 633;N-[2-Chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-propylurea;1-(2-chloro-4-(6,7-diMethoxyquinazolin-4-yloxy)phenyl)-3-propylurea;N-[2-Chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-propylurea KRN633;VEGFR Tyrosine Kinase Inhibitor III, KRN633;KRN 633;KRN-633;CS-463;KRN633; KRN-633; KRN 633 | | CAS: | 286370-15-8 | | MF: | C20H21ClN4O4 | | MW: | 416.86 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 286370-15-8.mol |  |
| | KRN 633 Chemical Properties |
| Melting point | 231-232°C | | Boiling point | 545.6±50.0 °C(Predicted) | | density | 1.321 | | storage temp. | -20°C | | solubility | DMSO: soluble3mg/mL, clear (warmed) | | pka | 13.08±0.70(Predicted) | | form | powder | | color | white to beige | | InChI | 1S/C20H21ClN4O4/c1-4-7-22-20(26)25-15-6-5-12(8-14(15)21)29-19-13-9-17(27-2)18(28-3)10-16(13)23-11-24-19/h5-6,8-11H,4,7H2,1-3H3,(H2,22,25,26) | | InChIKey | VPBYZLCHOKSGRX-UHFFFAOYSA-N |
| Hazard Codes | Xn | | Risk Statements | 22 | | WGK Germany | 3 | | Storage Class | 13 - Non Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral |
| | KRN 633 Usage And Synthesis |
| Uses | KRN 633 is an ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 170 nM/160 nM/125 nM and also inhibits PDGFRα/β with IC50 of 965 nM/9850 nM. | | Uses | KRN 633 is an ATP-competitive inhibitor of vascular endothlial growth factor receptor tyrosine kinase (VEGFR). KRN 633 also suppresses VEGF-dependent activation of MAPK and cell proliferation and demonstrates antitumor and antiangiogenic activity by inhibiting vessel formation and vascular permeability in human tumor xenograft models. | | Biological Activity | krn 633 is a selective inhibitor of vegfr-1, vegfr-2 and vegfr-3 with ic50 value of 170 nm, 160 nm and 125 nm [1].vascular endothelial growth factor receptor (vegfr) is a protein and plays an important role in tumor angiogenesis by cooperating with its ligand vegf [1].krn 633 is a potent vegfr inhibitor. when tested with huvecs, krn 633 inhibited the cell proliferation that mediated by vegf with the ic50 value of 14.9 nmol/l and suppressed the capillary tube formation by ~50% at the dose of 10 nmol/l [1].in mid-pregnant mice model, krn633 was used at the dose of 5 mg/kg once daily from embryonic day 13.5 until the day of delivery and the effect on vascular growth was slightly delayed on postnatal day 4 (p4) and on p8 it was observed that krn633 resulted in the decreased numbers of central arteries and veins and abnormal branching of the central arteries [2]. when tested with athymic mouse xenograft ht29 cells model, administration of krn633 inhibited tumor growth as ~90% from the initial tumor volume rangs from 500-667 mm3, while had less effect du145 xenograft mouse models by inhibiting tumor angiogenesis and vascular permeability [1]. | | Biochem/physiol Actions | KRN633 is a cell-permeable; reversible and ATP-competitive inhibitor of vascular endothelial growth factor receptor tyrosine kinase (VEGFR) with IC50 values of 170, 160, and 125 nM for VEGFR-1, -2, -3, respectively. Krn633 inhibits PDGFR-α and c-Kit only at higher concentrations (IC50 = 0.97 and 4.33 μM, respectively) and is inactive towards a panel of 17 other kinases (IC50 >/= 10 μM). | | Synthesis | Example 62 N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-propylurea was synthesized as follows: 2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]aniline (5.13 g) was dissolved in a solvent mixture of chloroform (100 mL) and triethylamine (50 mL). Subsequently, a solution of chloroform (3 mL) of triphosgene (4.59 g) was slowly added to this solution. The reaction mixture was stirred at room temperature for 30 minutes. Next, n-propylamine (2.74 g) was added to the reaction system and stirring was continued for 2 hours. Upon completion of the reaction, saturated aqueous sodium bicarbonate solution was added to the reaction solution for neutralization, followed by extraction with chloroform. The organic phase was dried with anhydrous sodium sulfate, filtered and concentrated under reduced pressure to remove the solvent. The crude product was purified by silica gel column chromatography with chloroform/methanol (50:1, v/v) as eluent to afford the target product N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-propylurea in 4.14 g in 64% yield. The structure of the product was confirmed by 1H-NMR (DMSO-d6, 400 MHz) and mass spectrometry (ESI-MS).1H-NMR data: δ 0.91 (t, J = 7.3 Hz, 3H), 1.41-1.53 (m, 2H), 3.05-3.12 (m, 2H), 3.97 (s, 3H), 3.99 (s, 3H). 6.99 (t, J = 5.4 Hz, 1H), 7.22 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.38 (s, 1H), 7.46 (d, J = 2.9 Hz, 1H), 7.54 (s, 1H), 8.04 (s, 1H), 8.20 (d, J = 9.3 Hz, 1H), 8.55 (s, 1H). Mass spectral data: m/z 417 (M++1). | | in vivo | KRN-633 inhibits tumor growth in several tumor xenograft models with diverse tissue origins, including lung, colon, and prostate, in athymic mice and rats. KRN-633 also causes the regression of some well-established tumors and those that have regrown after the cessation of treatment. KRN-633 is well tolerated and has no significant effects on body weight or the general health of the animals. Histologic analysis of tumor xenografts treated with KRN-633 reveals a reduction in the number of endothelial cells in non-necrotic areas and a decrease in vascular permeability[1]. | | target | VEGFR3 | | IC 50 | VEGFR1: 170 nM (IC50); VEGFR2: 160 nM (IC50); VEGFR3: 125 nM (IC50) | | references | [1]. nakamura, k., et al., krn633: a selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth. mol cancer ther, 2004. 3(12): p. 1639-49.
[2]. morita, a., et al., treatment of mid-pregnant mice with krn633, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, induces abnormal retinal vascular patterning in their newborn pups. birth defects res b dev reprod toxicol, 2014. 101(4): p. 293-9. |
| | KRN 633 Preparation Products And Raw materials |
|